Application of neochlorogenic acid and bilobalide C in preparation of product for inhibiting acetylcholin esterase
Through the combination of neochlorogenic acid and ginkgolactone C, the activity of acetylcholinesterase is significantly inhibited, and the problems of limited efficacy and major side effects of existing acetylcholinesterase inhibitors are solved, and an efficient and safe treatment plan for Alzheimer's disease is provided. It has significant synergistic effects and low toxicity.
Patent Information
- Application Number
- CN202411041081.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
Existing acetylcholinesterase inhibitors have limited efficacy and great side effects, making it difficult to provide efficient and safe drugs for treating Alzheimer's disease.
Using a mixture of neochlorogenic acid and ginkgolactone C, the activity of acetylcholinesterase was significantly inhibited through the joint action site and mechanism, and the inhibition rate reached 90.24%, which was better than the existing market-approved acetylcholinesterase inhibitor. Clint.
The combination of neochlorogenic acid and ginkgolactone C not only effectively inhibits acetylcholinesterase activity, but also has lower toxicity and higher biocompatibility, reducing side effects of gastric, liver and intestinal discomfort, and providing Alzheimer's disease Effective prevention and treatment and prevention drug candidates for diseases.
Smart Images

Figure CN118948824A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of acetylcholinesterase inhibitors, and particularly relates to the application of neochlorogenic acid and ginkgolide C in the preparation of products for inhibiting acetylcholinesterase. Background Art
[0002] Alzheimer's disease, also known as Alzheimer's, is the most common type of senile dementia and one of the neurodegenerative diseases of the brain. Its typical clinical features are degeneration of brain function, such as memory loss, social impairment, and loss of daily self-care ability. Alzheimer's disease is a disease that seriously affects the quality of life and physical health of the elderly after heart disease, tumors, and diabetes. It has become one of the leading causes of death in developed countries. The cause of Alzheimer's disease is still unknown. The internationally recognized pathogenesis of Alzheimer's disease includes the cholinergic deficiency theory, Aβ toxicity hypothesis, Tau protein hypothesis, insulin hypothesis, free radical damage hypothesis, etc.
[0003] Acetylcholinesterase is a key target for the treatment of Alzheimer's disease. It catalyzes the cleavage reaction of acetylcholine, reduces the level of neurotransmitters, affects the signal transmission between neurons, and then induces cognitive impairment. Therefore, inhibiting the activity of acetylcholinesterase can prevent the loss of acetylcholine and maintain the normal transmission of neural signals, becoming an effective strategy for the treatment of Alzheimer's disease.
[0004] So far, four acetylcholinesterase inhibitors have been recognized by the world medical community and approved by the FDA: tacrine, donepezil, rivastigmine and galantamine. However, these drugs have limited efficacy, are expensive, and are prone to cause side effects such as stomach, liver and intestinal discomfort in patients, which seriously restricts their application. Therefore, it has become a top priority to develop and study natural acetylcholinesterase inhibitors and provide efficient and safe drugs for the treatment of Alzheimer's disease. Summary of the invention
[0005] In view of the problems existing in the above-mentioned prior art, the present invention provides the use of neochlorogenic acid and ginkgolide C in the preparation of products inhibiting acetylcholinesterase, specifically, the use of one or two of neochlorogenic acid and ginkgolide C in a mixture. Compared with the prior art, the present invention uses one or two of neochlorogenic acid and ginkgolide C to effectively inhibit the activity of acetylcholinesterase, with an inhibition rate as high as 90.24%, and the inhibition effect is better than the acetylcholinesterase inhibitor tacrine currently approved on the market.
[0006] The above-mentioned object of the present invention is achieved by the following technical solutions:
[0007] One of the objects of the present invention is to provide the use of neochlorogenic acid and ginkgolide C in the preparation of products for inhibiting acetylcholinesterase, characterized in that one or two of neochlorogenic acid and ginkgolide C are used in mixture, wherein, when neochlorogenic acid or ginkgolide C is used in the preparation of products for inhibiting acetylcholinesterase, the usage amount is 1 mg / mL to 1.5 mg / mL; when the mixture of neochlorogenic acid and ginkgolide C is used in the preparation of products for inhibiting acetylcholinesterase, the usage amount of the mixture is 1 mg / mL to 1.5 mg / mL.
[0008] Preferably, the product comprises neochlorogenic acid and ginkgolide C.
[0009] Preferably, the mass ratio of neochlorogenic acid to ginkgolide C is 1-5:1-5.
[0010] Preferably, the mass ratio of neochlorogenic acid to ginkgolide C is 2:4.
[0011] Preferably, the acetylcholinesterase inhibition product further comprises one or more of a pharmaceutically acceptable carrier, excipient, diluent and auxiliary material.
[0012] Preferably, the carrier, excipient, diluent and auxiliary material include one or more of lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
[0013] Preferably, the acetylcholinesterase inhibition product is used to prepare a drug for treating acetylcholinesterase diseases.
[0014] Preferably, the acetylcholinesterase inhibiting product is used for preparing a drug for preventing acetylcholinesterase diseases.
[0015] Preferably, the acetylcholinesterase disease is Alzheimer's disease.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] 1. The present invention provides the use of neochlorogenic acid and ginkgolide C in the preparation of products for inhibiting acetylcholinesterase, specifically, the use of one or two of neochlorogenic acid and ginkgolide C in a mixture. When the usage amount is 1.0 mg / mL, neochlorogenic acid, ginkgolide C, and the mixture of neochlorogenic acid and ginkgolide C all show significant ability to inhibit the activity of acetylcholinesterase, and neochlorogenic acid and ginkgolide C show good synergistic effect in inhibiting the activity of acetylcholinesterase. The optimal ratio is selected and added to the excipients to prepare different preparations, which provides candidate drugs for the prevention and treatment of Alzheimer's disease, and has important economic value and social significance for the development and utilization of medicinal plants.
[0018] 2. Compared with the prior art, the use of the new chlorogenic acid and ginkgolide C of the present invention in the preparation of products for inhibiting acetylcholinesterase can not only effectively inhibit the activity of acetylcholinesterase, but also achieve an inhibition rate of 83.18% to 90.24%, and the inhibition effect is better than that of tacrine, an acetylcholinesterase inhibitor currently approved on the market.
[0019] 3. Both neochlorogenic acid and ginkgolide C are derived from natural plants, have higher biocompatibility and lower toxicity. Therefore, compared with other acetylcholinesterase inhibitors, the use of the neochlorogenic acid and ginkgolide C of the present invention in the preparation of products for inhibiting acetylcholinesterase has the ability to reduce the side effects of stomach, liver and intestinal discomfort. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is the structural formula diagram of the novel chlorogenic acid of the present invention;
[0021] Figure 2 It is the structural formula diagram of Ginkgolide C of the present invention. DETAILED DESCRIPTION
[0022] The present invention is described in detail below in conjunction with specific examples, but it should not be construed as limiting the present invention. The experimental methods in the following examples where specific conditions are not specified are all carried out according to conventional methods and conditions in the art. The equipment and materials used in the following examples are all commercially available unless otherwise specified.
[0023] Reagents and materials used in the present invention: neochlorogenic acid and ginkgolide C, Baoji Chenguang Biotechnology Co., Ltd., acetylcholinesterase, Sigma, dithiodinitrobenzoic acid, Sigma, positive control tacrine, Sigma, iodinated acetylthiocholine, Aladdin, 5,5-dithiobis(2-nitrobenzoic acid), Aladdin, and other reagents are imported or domestic analytical grade.
[0024] The apparatus and equipment of the present invention include: a spectrophotometer; an ultrapure water system; and a constant temperature water bath.
[0025] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by ordinary technicians in the technical field to which the present invention belongs.
[0026] Acetylcholinesterase inhibitors, such as anticholinesterase drugs, are a class of indirect cholinergic drugs that inhibit the activity of acetylcholinesterase, leading to an increase in the concentration of acetylcholine at the synapse, thereby enhancing and prolonging the effect of acetylcholine. When choline excites nerves, free acetylcholine is released, which enters the synaptic cleft and is catalytically hydrolyzed after binding to acetylcholinesterase, resulting in the termination of nerve impulse transmission. Acetylcholinesterase inhibitors inhibit the activity of acetylcholinesterase by binding to acetylcholinesterase and binding firmly, slowing down the hydrolysis process of acetylcholinesterase.
[0027] Ginkgolide C is a flavonoid isolated from Ginkgo biloba leaves. Its structural formula is as follows: Figure 1 As shown, it has multiple biological functions, including reducing platelet aggregation and improving Alzheimer's disease. Ginkgolide C can bind to the active site of acetylcholinesterase and block its hydrolysis of acetylcholine. This inhibitory effect can increase the concentration of acetylcholine in the synaptic cleft, thereby enhancing and prolonging the effect of acetylcholine.
[0028] Neochlorogenic acid is a polyphenolic compound extracted from honeysuckle with multiple biological activities. Its structural formula is as follows: Figure 2 As shown in Figure 2, neochlorogenic acid can bind to the active site of acetylcholinesterase, inhibit the activity of the enzyme, and then slow down the hydrolysis of acetylcholine. Under normal physiological conditions, acetylcholine is rapidly hydrolyzed by acetylcholinesterase after being released in the synaptic cleft to maintain the balance and normal conduction of nerve conduction. This inhibition can lead to the accumulation of acetylcholine in the synaptic cleft, thereby producing a cholinergic effect.
[0029] The application of neochlorogenic acid and ginkgolide C in the preparation of products for inhibiting acetylcholinesterase. When neochlorogenic acid and ginkgolide C are used in combination, the inhibition of acetylcholinesterase produces a significant synergistic effect, which means that the inhibitory effect of the mixture is stronger than that of either neochlorogenic acid or ginkgolide C alone. This synergistic effect stems from the fact that neochlorogenic acid and ginkgolide C have different action sites or mechanisms when inhibiting acetylcholinesterase. Neochlorogenic acid and ginkgolide C can act on acetylcholinesterase together, inhibiting its activity through different pathways, thereby producing a stronger inhibitory effect.
[0030] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in combination with specific embodiments and comparative examples.
[0031] Example 1
[0032] Application of neochlorogenic acid and ginkgolide C in the preparation of an acetylcholinesterase inhibiting product, the application method being: using neochlorogenic acid as an acetylcholinesterase inhibiting product to obtain a 1# acetylcholinesterase inhibiting product;
[0033] The 1# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample A.
[0034] Example 2
[0035] Application of neochlorogenic acid and ginkgolide C in the preparation of an acetylcholinesterase inhibition product, the application method is: using a baseline geometric increase and decrease design method, weighing drugs according to a mass ratio of neochlorogenic acid to ginkgolide C of 5:1, mixing them as an acetylcholinesterase inhibition product, and obtaining a 2# acetylcholinesterase inhibition product;
[0036] The 2# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample B.
[0037] Example 3
[0038] Application of neochlorogenic acid and ginkgolide C in the preparation of an acetylcholinesterase inhibition product, the application method is: using a baseline geometric increase and decrease design method, weighing drugs according to a mass ratio of neochlorogenic acid to ginkgolide C 4:2, mixing them as an acetylcholinesterase inhibition product, and obtaining a 3# acetylcholinesterase inhibition product;
[0039] The 3# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample C.
[0040] Example 4
[0041] Application of neochlorogenic acid and ginkgolide C in the preparation of an acetylcholinesterase inhibition product, the application method is: using a baseline geometric increase and decrease design method, weighing drugs according to a mass ratio of neochlorogenic acid to ginkgolide C of 3:3, mixing them as an acetylcholinesterase inhibition product, and obtaining a 4# acetylcholinesterase inhibition product;
[0042] The 4# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample D.
[0043] Example 5
[0044] Application of neochlorogenic acid and ginkgolide C in the preparation of an acetylcholinesterase inhibition product, the application method is: using a baseline geometric increase and decrease design method, weighing drugs according to a mass ratio of neochlorogenic acid to ginkgolide C 2:4, mixing them as an acetylcholinesterase inhibition product, and obtaining a 5# acetylcholinesterase inhibition product;
[0045] The 5# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample E.
[0046] Example 6
[0047] The application of neochlorogenic acid and ginkgolide C in the preparation of an acetylcholinesterase inhibition product is as follows: a baseline geometric increase and decrease design method is used, and the drugs are weighed according to a mass ratio of neochlorogenic acid to ginkgolide C of 1:5, and the mixture is used as an acetylcholinesterase inhibition product to obtain a 6# acetylcholinesterase inhibition product;
[0048] The 6# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample F.
[0049] Example 7
[0050] Application of neochlorogenic acid and ginkgolide C in the preparation of products inhibiting acetylcholinesterase, the application method is: using ginkgolide C as the product inhibiting acetylcholinesterase to obtain 7# acetylcholinesterase inhibiting product;
[0051] The 7# acetylcholinesterase inhibition product was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as sample G.
[0052] Comparative Example 1
[0053] Tacrine was used as a product for inhibiting acetylcholinesterase. Tacrine was added to 50% ethanol by volume to obtain a 1 mg / mL sample solution, which was recorded as a positive control sample.
[0054] The inhibitory effects of the samples obtained from Examples 1 to 7 of the present invention and Comparative Example 1 on acetylcholinesterase activity were studied:
[0055] a. Acetylcholinesterase activity test:
[0056] Test method:
[0057] Take 30 μL of the sample solution, add 795 μL of polybutylene succinate with pH = 8.0, 15 μL of 0.85 U / mL acetylcholinesterase solution, shake evenly, preheat at 37 ° C for 2 min, then add to 30 μL of 0.015 mol / L 5,5-dithiobis (2-nitrobenzoic acid) and 30 μL of 0.015 mol / L iodinated acetylthiocholine solution, react at 37 ° C for 15 min, add 300 μL , 4% by mass of sodium dodecyl sulfate was added to terminate the reaction, and the absorption value at 412nm was measured by a spectrophotometer, which was recorded as sample A; at the same time, 50% by volume of ethanol was used to replace the sample solution, and its absorbance was recorded as blank A; another sample blank was made, that is, 75 μL of polybutylene succinate was used to replace the enzyme solution, 5,5-dithiobis(2-nitrobenzoic acid) and iodinated acetylthiocholine, which was recorded as sample blank A, and the absorbance was measured at 412nm and the inhibition rate was calculated according to the following formula.
[0058] Sample group: Inhibition rate (%) = [A blank - (A sample - A sample blank)] / A blank × 100%
[0059] Positive control: inhibition rate (%) = [A blank - (A positive control - A positive blank)] / A blank × 100% All operations were repeated twice and the average value was calculated. The positive control was tacrine.
[0060] In order to verify the effect of the present invention, the inhibitory effect of each sample ratio on acetylcholinesterase activity was detected by colorimetry.
[0061] When the concentration is 1.0 mg / mL, the inhibition rate of samples A to G and the samples shown in Comparative Example 1 on acetylcholinesterase activity is shown in Table 1:
[0062] Table 1 Inhibition rate of acetylcholinesterase activity of samples of Example 1 to Example 7 and Comparative Example 1
[0063] sample A B C D E F G Comparative Example 1 Inhibition rate / % 83.18 86.98 88.43 86.75 90.24 86.48 86.98 80.12
[0064] The experimental results show that the mixtures of different mass ratios of neochlorogenic acid and ginkgolide C set by the baseline geometric increase and decrease design method, i.e., samples B to F, at 1.0 mg / mL, generally have a higher inhibition rate on acetylcholinesterase activity than the use of neochlorogenic acid alone, i.e., sample A or ginkgolide C, i.e., sample G. In particular, when the mass ratio of neochlorogenic acid to ginkgolide C reaches 2:4, i.e., sample E, the inhibition rate is the highest, reaching 90.24%, showing a significant synergistic effect. Compared with the positive control sample tacrine, the use of one or two of the neochlorogenic acid and ginkgolide C in the present invention shows a better effect in inhibiting acetylcholinesterase activity, providing valuable resources for the development of new acetylcholinesterase inhibitors, and also providing new candidate drugs for the prevention and treatment of Alzheimer's disease, which has important economic value and social significance for the development and utilization of medicinal plants.
[0065] b. Acetylcholinesterase inhibitory activity
[0066] The one-shot passive avoidance test is a widely used experimental method in the field of scientific research to evaluate the learning and memory abilities of rodents. This test usually involves the use of scopolamine to simulate passive avoidance impairment in rodents, and the use of acetylcholinesterase inhibitors to observe their effects on this impairment, as a screening test to predict potential acetylcholinesterase inhibitors as anti-dementia drugs.
[0067] Passive avoidance test
[0068] Research subjects: 20 SPF male Kunming mice, aged 3-4 months, weighing 22g-25g, kept in an environment with a temperature of 18℃-22℃, a humidity of 50%-60%, 12h alternating light and dark lighting, free diet, and adaptive feeding for 7 days;
[0069] Mice were subjected to a one-time passive avoidance test as described by Brioni;
[0070] The passive avoidance test was performed in a computerized shuttle box with the software program PACS30, which contained two chambers separated by an automatic door. After a 30-second exploration period to allow the animals to adapt to the environment, a 270-second test was performed. During the test, the mice were placed in the bright chamber and once they stepped into the dark chamber, an electric grid on the floor would be triggered immediately, applying a brief electric shock to them. The electric shock condition was set to a current of 0.5 mA for 5 seconds, and the transfer latency of the mice from the bright chamber to the dark chamber was recorded in seconds. The transfer latency of the control and treatment groups was recorded and recorded again after 24 hours. The increase obtained in the second test relative to the first test was taken as an indicator of successful learning and cognitive ability.
[0071] Scopolamine-induced cognitive impairment: Scopolamine, as a carcinoma antagonist, has been widely recognized for its significant inhibitory effect on cognitive function in humans and experimental animals. Therefore, scopolamine was deliberately used as a tool to induce cognitive impairment in the passive avoidance learning test. Specifically, scopolamine was administered five minutes before the start of the first test to simulate and aggravate the animals' decline in memory and learning ability; if the animals' learning and memory abilities did not increase significantly in the second test, it was considered that scopolamine successfully caused impairment.
[0072] Drug administration: The samples of Examples 1 to 7 were orally administered with 1% arabic gum suspension at a dose of 60 mL / kg for 3 days. The first test was performed on the test mice 60 minutes after the third administration of the samples of Examples 1 to 7, and scopolamine was administered 5 minutes before the first test.
[0073] The control group was orally administered with a 1% aqueous suspension of gum arabic at a dose of 1 mL / kg for 3 days. Half of the control group mice were administered scopolamine 5 minutes before the first test to simulate control dementia, and the remaining half were subjected to a passive avoidance test to simulate control training.
[0074] The transfer latency of the control group in the second test was significantly increased compared to the first test, showing successful learning and memory functions. The mice treated with scopolamine did not show impairment of learning and memory abilities in the second test. Mice pretreated with samples A, B, C, D, E, F and G still showed a significant improvement in memory ability after scopolamine treatment. The most effective of these samples is sample E, which can prevent memory damage caused by scopolamine. At the same time, samples A, B, C, D, E, F and G are shown to have effective anti-dementia activity.
[0075] Based on the memory retention rate, i.e., the percentage increase of the transfer latency of the second test relative to the transfer latency of the first test, the effects of sample A, sample B, sample C, sample D, sample E, sample F and sample G (30 mg / kg, oral) and the standard drug tacrine (10 mg / kg, oral) on the memory impairment caused by scopolamine in the passive avoidance test were compared. As shown in Table 2, the comparative data of the samples of Examples 1 to 7 of the present invention and the standard drug tacrine.
[0076] Table 2 Comparison data of samples of Examples 1 to 7 of the present invention and the standard drug tacrine
[0077] Group Memory retention / % Control training 496 Control dementia 35 A 289 B 316 C 354 D 308 E 392 F 302 G 325 Tacrine 276
[0078] As shown in Table 2, in the scopolamine-induced cognitive impairment model, the samples in Examples 1 to 7, i.e., Samples A to G, all showed different degrees of anti-dementia activity and memory protection effects, among which Sample E had the most significant effect, with a memory retention rate of up to 392%, exceeding the memory retention rate of the standard drug tacrine. These results show that Samples A, B, C, D, E, F, and G have potential medicinal value for preventing and treating cognitive impairment and dementia diseases, and in particular, Sample E showed particularly excellent performance, providing valuable candidate samples for the future development of dementia drugs.
[0079] It should be noted that when the claims and the specification of the present invention involve a numerical range, it should be understood that the two endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as those in the embodiments, in order to avoid redundancy, the present invention describes the preferred embodiments. Although the preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they know the basic creative concept. Therefore, the attached claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0080] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. Application of neochlorogenic acid and ginkgolide C in the preparation of products for inhibiting acetylcholinesterase, characterized in that: One or two of neochlorogenic acid and ginkgolide C are used in mixture, wherein when neochlorogenic acid or ginkgolide C is used in the preparation of products inhibiting acetylcholinesterase, the usage amount is 1 mg / mL to 1.5 mg / mL; when the mixture of neochlorogenic acid and ginkgolide C is used in the preparation of products inhibiting acetylcholinesterase, the usage amount of the mixture is 1 mg / mL to 1.5 mg / mL.
2. The use of the new chlorogenic acid and ginkgolide C according to claim 1 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The product includes neochlorogenic acid and ginkgolide C.
3. The use of the new chlorogenic acid and ginkgolide C according to claim 2 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The mass ratio of neochlorogenic acid to ginkgolide C is 1-5:1-5.
4. The use of the new chlorogenic acid and ginkgolide C according to claim 3 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The mass ratio of neochlorogenic acid to ginkgolide C is 2:
4.
5. The use of the new chlorogenic acid and ginkgolide C according to claim 1 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The acetylcholinesterase inhibition product further comprises one or more of a pharmaceutically acceptable carrier, excipient, diluent and auxiliary material.
6. The use of the new chlorogenic acid and ginkgolide C according to claim 5 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The carrier, excipient, diluent and auxiliary material include one or more of lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.
7. The use of the new chlorogenic acid and ginkgolide C according to claim 1 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The acetylcholinesterase inhibition product is used for preparing medicines for treating acetylcholinesterase diseases.
8. The use of the new chlorogenic acid and ginkgolide C according to claim 1 in the preparation of a product for inhibiting acetylcholinesterase, characterized in that: The acetylcholinesterase inhibition product is used for preparing medicines for preventing acetylcholinesterase diseases.
9. The use according to claim 7 or 8, characterized in that: The acetylcholinesterase disease is Alzheimer's disease.
Citation Information
Patent Citations
Application of chlorogenic acid in preparing medicines for preventing and curing senile dementia
CN101732301A
